Medication info

Sitavis M Tablet 50/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Kukje Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
28 tablets (14 tablets/PTP×2), 56 tablets (14 tablets/PTP×4)
Approval status
Expired

MFDS item code 201505755 · Approved 2015.08.18

This product's status changed to Expired on 2025.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Kukje Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

View approved original text

This medication is used to assist patients with type 2 diabetes in controlling blood sugar when combined with diet and exercise. Sitagliptin and Metformin work together to effectively lower and manage blood sugar levels. Therefore, this medication is used as an adjunct therapy to improve your blood sugar control.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication helps to control blood sugar levels. However, there are several precautions to consider when taking this medication. Firstly, an allergic reaction may occur; if symptoms such as rash or difficulty breathing appear, discontinue use immediately and consult a physician. Additionally, acute pancreatitis, a serious pancreatic disorder, may occur rarely, so if you experience symptoms such as abdominal pain, nausea, or vomiting, go to the hospital immediately. One component of this medication, Metformin, can be dangerous for patients with decreased kidney function, and may cause lactic acidosis, a serious metabolic disorder, so kidney function tests should be performed regularly. In particular, patients with moderate to severe renal impairment, those with severe infections or dehydration, patients with heart failure, and pregnant or nursing women should not take this medication. During treatment, hypoglycemia may occur, so care should be taken during missed meals or vigorous exercise, and the risk of hypoglycemia may increase when taken with other blood sugar lowering agents. Moreover, this medication requires caution in patients with liver dysfunction, and alcohol intake may increase the risk of lactic acidosis, so it should be avoided. If undergoing surgery or undergoing iodinated contrast tests, this medication should be temporarily discontinued and restarted only after kidney function has recovered. Routine checks of blood sugar, renal function, liver function, and vitamin B12 levels should be done during treatment, and any abnormal symptoms should be reported to healthcare providers immediately. Lastly, this medication is not recommended for children under 18 years of age as safety and efficacy have not been established.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe joint pain accompanied by disabilities, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, vitamin B12 deficiency, rash, urticaria, cutaneous vasculitis, elevated liver enzyme levels, acute renal failure, dyspnea, unstable angina, dizziness, decreased appetite, gastrointestinal disorders, itching, weight loss, severe hypoglycemia, anorexia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that does not allow air in, preferably at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication and prevents degradation.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

28 tablets (14 tablets/PTP×2), 56 tablets (14 tablets/PTP×4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.